Alkermes Appoints Nancy S. Lurker to Board

Alkermes PLC (NASDAQ: ALKS) has announced the appointment of Nancy S. Lurker as a new independent director to the company's board of directors. Lurker is a seasoned healthcare executive with extensive experience in the pharmaceutical and biotechnology industry, including successful U.S. and global pharmaceutical product launches. This appointment signals the company's dedication to advancing its important work in bringing innovative medicines to patients living with serious neurological and psychiatric conditions.

Nancy Lurker most recently served as the Chief Executive Officer of EyePoint Pharmaceuticals, Inc., a publicly-traded specialty biopharmaceutical company, from 2016 to July 2023, and currently holds the position of Executive Vice Chair of EyePoint Pharmaceuticals' board of directors. She has also held leadership roles in other prominent pharmaceutical companies such as Novartis Pharmaceuticals Corporation and Pharmacia Corporation.

Lurker's appointment reflects Alkermes' commitment to robust board refreshment and diversity, aligning the qualifications and experience of directors with the company's strategy and growth opportunities.

Alkermes PLC is a global biopharmaceutical company focused on developing innovative medicines in the field of neuroscience. The company's portfolio includes proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, as well as a pipeline of clinical and preclinical candidates in development for neurological disorders.

The market has reacted to these announcements by moving the company's shares 0.2% to a price of $29.0. For the full picture, make sure to review Alkermes's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.